January 10, 2017 — More than 250 women who went permanently bald after completing chemotherapy with Taxotere have filed lawsuits against the drug-maker for failing to warn about the risk.
All federal lawsuits nationwide are currently centralized in Multi-District Litigation (MDL No. 2740) in the Eastern District of Louisiana. There were only 33 cases when the MDL was created in October 2016.
As of December 15, 2016, the number of lawsuits in the Taxotere MDL has skyrocketed to 267 — a massive increase in less than 3 months.
Taxotere is a chemotherapy drug sold by Sanofi-Aventis that is commonly used to treat women with breast cancer. It has been available in the U.S. for more than two decades.
Warnings about reports of permanent hair loss were not added to the label until December 2015. Until those updates, the label reassured women that “hair generally grows back” after completing treatment.
In Canada, the label on Taxotere had warnings about permanent hair loss since 2005, and in Europe since 2012. Lawyers say Sanofi-Aventis knew about the side effect but did not warn women in the U.S.
One woman from California filed a lawsuit claiming that Sanofi-Aventis knew from a study in the 1990s that 9.2% of women who were given Taxotere, Adriamycin, and Cyclophosphamide (TAC) had hair loss that persisted for 10 years.
Do I have a Taxotere Lawsuit?
The Schmidt Firm, PLLC is currently accepting Taxotere induced injury cases in all 50 states. If you or somebody you know has been diagnosed with permanent hair loss, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.